WST

West Pharmaceutical Services, Inc. - 2008 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: West Pharmaceutical Services, Inc.
Reporting Period: Fiscal year ended December 31, 2008.
Business Overview: West is a global manufacturer of components and systems for injectable drug delivery and plastic packaging for healthcare and consumer products. The company operates through two reportable segments: Pharmaceutical Systems (packaging components like stoppers, seals, and syringe parts) and Tech Group (custom injection molding for healthcare and consumer industries). Approximately 54% of sales are generated outside the U.S.

Key Financial Metrics (2008)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 3.0% to $1,051.1 million. Growth was driven by improved pricing (2.3 percentage points) and favorable foreign currency translation, offset by lower volumes due to regulatory constraints and the discontinuation of certain products (lost sales of $63 million).
• Segment Performance:
  • Pharmaceutical Systems: Sales rose 6.8% to $792.1 million, driven by demand for enhanced packaging and safety systems, despite a $17.4 million decline in prefillable syringe components due to customer product issues.
  • Tech Group: Sales fell 6.5% to $270.5 million, primarily due to the loss of $33 million in sales related to the Exubera device (discontinued by Pfizer). However, operating profit increased 50% due to restructuring savings and efficiency gains.
• Profitability: Operating profit increased 30.7% to $124.1 million. This improvement was significantly aided by a $4.2 million net gain from contract settlement proceeds with Nektar (related to Exubera) and lower restructuring charges compared to 2007. In 2007, results were burdened by a $12.9 million impairment charge and $10.1 million in Brazilian tax provisions.
• Costs: R&D expenses increased to $18.7 million (from $16.1 million) due to new development projects. SG&A expenses rose slightly to $159.3 million, impacted by IT system implementation costs and foreign currency translation.

Guidance, Outlook, and Risks

• 2009 Outlook: Management expects consolidated sales to be between $1.01 billion and $1.03 billion, a decrease of 2% to 4% from 2008. This decline is primarily attributed to an anticipated unfavorable foreign exchange impact of approximately 7%. Excluding currency effects, organic growth is expected to be 3.0% to 5.0%.
• Segment Guidance:
  • Pharmaceutical Systems: Revenues expected to be marginally lower than 2008 due to currency headwinds (8% impact).
  • Tech Group: Revenues expected to be 5% to 7% lower than 2008, driven by currency (3% impact) and lower plastic resin costs passed to customers.
• Capital Spending: 2009 capital spending is budgeted at approximately $140 million, similar to 2008 levels, to fund capacity expansions in China, Europe, and the U.S.
• Key Risks:
  • Economic Conditions: Global financial market disruption and economic downturns could reduce demand and increase credit risk.
  • Foreign Currency: Significant exposure to the Euro, British Pound, and Japanese Yen; strengthening U.S. dollar negatively impacts reported sales.
  • Raw Materials: Volatility in elastomer, aluminum, and plastic prices; reliance on single-source suppliers for critical materials.
  • Pension Obligations: Poor investment performance in 2008 led to a significant increase in pension underfunding ($73.0 million), expected to increase 2009 pension expense by approximately $10 million.

Investor Verification Checklist

• Exubera Impact: Verify the extent to which the $4.2 million settlement gain offsets the permanent loss of Exubera-related revenue in the Tech Group segment.
• Currency Sensitivity: Assess the company's hedging strategies and the specific impact of the strengthening U.S. dollar on the 2009 revenue guidance.
• Pension Funding: Review the $73.0 million pension underfunded balance and the projected $10 million increase in 2009 pension expense to understand future cash flow requirements.
• Customer Concentration: Confirm that no single customer accounts for more than 10% of sales, though the top 10 customers represent 35.8% of total sales.
• IT Implementation: Monitor the progress and cost overruns of the SAP ERP implementation, which is ongoing through 2009 and critical to financial reporting.